Foundation Medicine to Present Over 15 Abstracts at the 2025 ASCO ® Annual Meeting
BOSTON--(BUSINESS WIRE)-- Foundation Medicine, Inc., a genomic company committed to transforming cancer care, today announced that the company and its collaborators will present more than 15 abstracts demonstrating the value of high-quality biomarker tests to inform cancer care at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from May 30 to June 3 in Chicago.
Foundation Medicine's research presented at the meeting will include new insights across breast cancer, lung cancer and prostate cancer, including an oral presentation highlighting the findings from the COMRADE phase 2 clinical trial in castration resistant prostate cancer, which leveraged the research use version of FoundationOne®Monitor, the company's tissue-free treatment response monitoring assay, for serial ctDNA analysis. (Abstract 5007, Tuesday, June 3, at 11:57 am – 12:09 pm CT, Hall D1)
'In partnership with over 30 clinical collaborators, Foundation Medicine's new research at the ASCO Annual Meeting further reinforces the important role high-quality biomarker testing plays in delivering personalized cancer care,' said Mia Levy, M.D., Ph.D., chief medical officer at Foundation Medicine. 'From exploring the role of innovative and complex biomarkers to expanding the clinical utility of genomic profiling, we are excited to demonstrate how our testing portfolio, including our new treatment response monitoring assay, can help providers make more informed treatment decisions for their patients.'
To access the abstracts being presented at the 2025 ASCO Annual Meeting, please visit ASCO.org/abstracts.
Follow Foundation Medicine on LinkedIn, X and Instagram for more updates from #ASCO25 and visit us in person at booth #27021.
Complete list of Foundation Medicine's abstracts at the 2025 ASCO Annual Meeting
Abstract Number
Title
Product
3570
Comparison of MET genomic alterations (GA) identified in colorectal cancer (CRC) vs gastric cancer (GCA)
FoundationOne®CDx
4153
Pancreatic adenosquamous carcinoma (PASC): A comparative genomic landscape study
FoundationOne®CDx
4183
BRCA1/2 and PALB2 short variants (SVs) contributed by clonal hematopoiesis (CH) in liquid biopsies (LBx) from patients with advanced pancreatic cancer (PC)
FoundationOne®CDx / FoundationOne®Liquid CDx
8036
Tumor type prediction via tissue- and liquid-based comprehensive genomic profiling: High-specificity tobacco signature detection to support lung cancer diagnosis
FoundationOne®CDx / FoundationOne®Liquid CDx
8039
Clinical utility of pathologist-directed comprehensive comparative molecular profiling for the classification of separate primary lung cancers vs. intrapulmonary metastasis
FoundationOne®CDx
8628
Association of circulating tumor DNA (ctDNA) variant allelic frequency (VAF) with outcomes on matched targeted therapies (TT) in advanced non-small cell lung cancer (aNSCLC)
FoundationOne®Liquid CDx
11161
Real-world analysis of factors influencing turnaround time (TAT) for tissue comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC)
FoundationOne®CDx
Sunday, June 1
5592
Distinguishing tumor vs. clonal hematopoiesis (CH)–derived TP53 and BRCA1/2 alterations in ovarian cancer liquid biopsies with a predictive algorithm to inform clinical decision-making
FoundationOne®CDx / FoundationOne®Liquid CDx
6528
Nucleophosmin (NPM1) genomic alterations (GA) in acute myeloid leukemia (AML): A genomic landscape study
FoundationOne®Heme
9520
Homologous recombination deficiency signature (HRDsig) in advanced cutaneous melanoma (ACM): A genomic landscape study
FoundationOne®CDx
Monday, June 2
1043
TP53 genomic alterations including targetable TP53 Y220C mutation in clinically advanced breast cancer
FoundationOne®CDx
1048
Genomic alterations (GAs) associated with durability of benefit from trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1) and sacituzumab govitecan (SG) in metastatic breast cancer (MBC)
FoundationOne®CDx / FoundationOne®Liquid CDx
1065
Quantifying the clinical impact of tissue reflex testing for liquid biopsy ESR1 mutation-negative cases with low ctDNA tumor fraction (TF) in HR(+)HER2(-) breast cancer
FoundationOne®CDx / FoundationOne®Liquid CDx
3081
Genomic landscape of 5'methylthioadenosine phosphorylase (MTAP) deleted (MTAP loss) non-squamous carcinoma of unknown primary site (nsCUP)
FoundationOne®CDx
5064
Additive clinical utility of tissue biomarkers of microsatellite instability (MSI) status and tumor mutational burden (TMB) to predict immune checkpoint inhibitor (ICI) effectiveness for real-world patients with metastatic castration-resistant prostate cancer (mCRPC)
FoundationOne®CDx
4564
Fibroblast growth factor receptor 3 (FGFR3) alteration status and outcomes with immune checkpoint inhibitors (ICPI) in patients with metastatic urothelial carcinoma
FoundationOne®CDx
Tuesday, June 3
5007
A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis
Expand
About Foundation Medicine
Foundation Medicine is a genomics company dedicated to transforming cancer care. We develop high-quality diagnostic tests that accurately identify the genomic mutations driving a patient's cancer, match a patient to the most effective treatment options, including targeted therapies, immunotherapies or clinical trials, and monitor a patient's response to treatment. For more information, please visit us on www.FoundationMedicine.com and follow us on LinkedIn, Instagram, X and YouTube.
About FoundationOne®CDx
FoundationOne®CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. FoundationOne CDx is for prescription use only and is intended as a companion diagnostic to identify patients who may benefit from treatment with certain targeted therapies in accordance with their approved therapeutic product labeling. Additionally, FoundationOne CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For a full list of targeted therapies for which FoundationOne CDx is indicated as a companion diagnostic, please visit www.F1CDxLabel.com.
About FoundationOne®Liquid CDx
FoundationOne®Liquid CDx is a qualitative next generation sequencing based in vitro diagnostic test for prescription use only that uses targeted high throughput hybridization-based capture technology to analyze 324 genes utilizing circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of advanced cancer patients. The test is FDA-approved to report short variants in over 300 genes and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and genomic alteration status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.
About FoundationOne®Heme
FoundationOne®Heme is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. FoundationOne Heme has not been cleared or approved by the U.S. Food and Drug Administration. For more information on FoundationOne Heme, please see its Technical Specifications at foundationmedicine.com/heme.
The test employs RNA sequencing in addition to DNA sequencing to simultaneously detect all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and rearrangements, and gene fusions.
*For Research Use Only. Not for use in diagnostic procedures.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
BMO Lifts CrowdStrike (CRWD) Price Target to $500, Cites Long-Term Growth Strength
We recently published a list of . In this article, we are going to take a look at where CrowdStrike Holdings, Inc. (NASDAQ:CRWD) stands against other buzzing AI stocks on latest news and ratings. On June 4th, BMO Capital raised the firm's price target on CrowdStrike Holdings, Inc. (NASDAQ:CRWD) to $500 from $405 and kept an 'Outperform' rating on the shares. Firm analysts cited CrowdStrike's 'solid if unspectacular' quarterly performance and comprehensive security portfolio as reasons behind the rating affirmation. The analysts also told investors in a research note how the company boasts one of the most comprehensive and effective security portfolios. Security personnel at their consoles, monitoring a global network of threats in real-time. Analysts also added that they are optimistic about the company's ability to sustain 20% top-line growth into fiscal year 2027. This growth projection aligns with its current revenue growth of 26% and projected 21% growth for the next fiscal year. Moreover, CrowdStrike's customer commitment packages anniversary is expected to boost annual recurring revenue growth in the second half of fiscal year 2026. Even though the analysts acknowledge the stock's high valuation, they are optimistic about its future performance. CrowdStrike Holdings, Inc. (NASDAQ:CRWD) is a leader in AI-driven endpoint and cloud workload protection. Overall, CRWD ranks 8th on our list of buzzing AI stocks on latest news and ratings. While we acknowledge the potential of CRWD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
3 hours ago
- Yahoo
Micron (MU) Ships World's First 1-Gamma LPDDR5X to Power Faster, Smarter AI Smartphones
We recently published a list of . In this article, we are going to take a look at where Micron Technology, Inc. (NASDAQ:MU) stands against other buzzing AI stocks on latest news and ratings. On June 3rd, Micron Technology, Inc. (NASDAQ:MU) announced shipping of the world's first 1γ (1-gamma) node-based low-power double data rate 5X (LPDDR5X) memory. Known to be a game-changer for the mobile industry, it has the ability to accelerate AI applications on flagship smartphones. The Micron LPDDR5X delivers faster, smoother mobile experiences and longer battery life for users. This is true even when operating data-intensive workloads such as AI-powered translation or image generation. A close-up view of a computer motherboard with integrated semiconductor chips. Next-generation smartphone designs are competing to be as compact as possible, and the LPDDR5X package size boasts to be the industry's thinnest package of 0.61 millimeters. This makes it 6% thinner compared to competitive offerings, and marks a 14% height reduction from the previous generation. As such, Micron's latest offering offers users a whopping 20% power savings, offering users the ability to enjoy their favorite AI applications, games, and video content longer on a single charge. Moreover, data center servers, intelligent vehicles, and AI PCs may also adopt the LPDDR5X for achieving optimized power efficiency and high performance. 'Micron's 1-gamma node-based LPDDR5X memory is a game-changer for the mobile industry. This breakthrough technology delivers lightning-fast speeds and remarkable power efficiency — all within the industry's thinnest LPDDR5X package — paving the way for exciting new smartphone designs. This solution demonstrates our commitment to empowering the ecosystem to create extraordinary mobile experiences.' Micron Technology, Inc. (NASDAQ:MU) develops and sells memory and storage products for data centers, mobile devices, and various industries worldwide. Overall, MU ranks 5th on our list of buzzing AI stocks on latest news and ratings. While we acknowledge the potential of MU as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Why AST SpaceMobile, Inc. (ASTS) Soared On Thursday
We recently published a list of . In this article, we are going to take a look at where AST SpaceMobile, Inc. (NASDAQ:ASTS) stands against other best-performing stocks on Thursday. AST SpaceMobile extended its winning streak to a fourth straight day on Thursday, jumping 7.53 percent to close at $30.85 apiece as investors scrambled to ride on the growth opportunities from a potential tie-up with billionaire Jeff Bezos. Earlier this week, speculations surfaced about a potential tie-up between AST SpaceMobile Inc. (NASDAQ:ASTS) and Blue Origin following an Instagram post by the former's board member, Adriana Cisneros, showing herself alongside CEO Abel Avellan and Bezos, in a photo. An aerial view of a communications satellite in orbit, beaming its signal down to Earth. She also captioned: 'Amazing things are happening at AST & Science + Blue Origin.' Prior to the Instagram post, Blue Origin executives visited the AST SpaceMobile, Inc. (NASDAQ:ASTS) headquarters in Texas, with speculations that discussions may have gone beyond launch logistics to cover broader strategic and financial matters. AST SpaceMobile, Inc. (NASDAQ:ASTS) already holds a major commercial agreement with Blue Origin for the launch of up to 45 BlueBird Block 2 satellites, with the option to add 15 more. Overall, ASTS ranks 10th on our list of best-performing stocks on Thursday. While we acknowledge the potential of ASTS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
